COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response
Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its rela...
Saved in:
Published in | Vaccine Vol. 61; p. 127420 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
13.08.2025
Elsevier Limited |
Subjects | |
Online Access | Get full text |
ISSN | 0264-410X 1873-2518 1873-2518 |
DOI | 10.1016/j.vaccine.2025.127420 |
Cover
Abstract | Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables.
CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age.
Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design. |
---|---|
AbstractList | AbstractSevere SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design. Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design. Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design. Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design.Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate factors driving diversity in the cellular immune response to vaccination. Here, we evaluated T-cell immunity in 60 healthy adults and its relationship to vaccine and subject-specific variables. CD4 and CD8 T-cells from COVID-19 vaccinated subjects expressed spike-specific activation-induced markers (AIM+) and cytokines. Overall, AIM+ CD8 T-cells correlated best with neutralizing antibodies and were more strongly expressed by females than males. Unique patterns in CD4 T-regulatory cells, cytokine profiles, and central and effector memory subsets were observed between Moderna, Pfizer, and Janssen vaccinees and by subject-specific factors. Sex differences outweighed differences in BMI and age. Thus, COVID-19 vaccine type and subject sex impacted the magnitude and quality of the spike-specific T-cell response. These results help explain differences in durability and memory between mRNA and adenovirus vector based COVID-19 vaccines and suggest targets for improved vaccine design. |
ArticleNumber | 127420 |
Author | Tong, Sherry Robinson, James E. Litwin, Sean M. Drury, Stacy S. Prather, Aric A. Hecht, Frederick M. Lin, Jue Norton, Elizabeth B. Epel, Elissa S. |
Author_xml | – sequence: 1 givenname: Sherry surname: Tong fullname: Tong, Sherry organization: Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America – sequence: 2 givenname: Sean M. surname: Litwin fullname: Litwin, Sean M. organization: Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America – sequence: 3 givenname: Elissa S. surname: Epel fullname: Epel, Elissa S. organization: Center for Health and Community, University of California, San Francisco, CA, United States of America – sequence: 4 givenname: Jue surname: Lin fullname: Lin, Jue organization: Department of Biochemistry and Biophysics, University of California, San Francisco, CA, United States of America – sequence: 5 givenname: Stacy S. surname: Drury fullname: Drury, Stacy S. organization: Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States of America – sequence: 6 givenname: Frederick M. surname: Hecht fullname: Hecht, Frederick M. organization: Department of Medicine, University of California, San Francisco, CA, United States of America – sequence: 7 givenname: James E. surname: Robinson fullname: Robinson, James E. organization: Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, United States of America – sequence: 8 givenname: Aric A. surname: Prather fullname: Prather, Aric A. organization: Center for Health and Community, University of California, San Francisco, CA, United States of America – sequence: 9 givenname: Elizabeth B. surname: Norton fullname: Norton, Elizabeth B. email: enorton@tulane.edu organization: Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, LA, United States of America |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40561567$$D View this record in MEDLINE/PubMed |
BookMark | eNqNks9uEzEQxi1URNPCI4AsceGywfba3vUBUBT-Vaqo1JSKm-X1joXDxhvsbETehmfhyfBqQw-VEBwsy5rffDP-Zs7QSegDIPSUkjklVL5cz_fGWh9gzggTc8oqzsgDNKN1VRZM0PoEzQiTvOCUfDlFZymtCSGipOoROuVESCpkNUPt8ur24m1BFd5cf1rgPuK9j6bDe7C78THVwLvDFrAJLU5Ds84hnOAH9sF1AwSbw18BrxbXq2LZ3xbs18-bwkLX4Qhp24cEj9FDZ7oET473Ofr8_t3N8mNxefXhYrm4LCxXaldII0vgrjUA-TQUXFMLCspRrmyjpGDSKcVpVVkliKwrJQBK58rSSSlMXZ6jF5PuNvbfB0g7vfFp7MQE6IekS8Y4E7ziIqPP76Hrfoghd5cpzspKUEIy9exIDc0GWr2NfmPiQf_xLwNiAmzsU4rg7hBK9DgnvdZHD_U4Jz3NKee9mfIg27H3EHWyfrSy9THbq9ve_1Ph9T0F2_ngrem-wQHS3W-oTkwTvRp3YVwFJgipaDUKvPq7wH808BvPK8TO |
Cites_doi | 10.1126/sciimmunol.abl5344 10.1038/s41586-022-04460-3 10.1056/NEJMoa2034577 10.1016/j.cell.2022.01.015 10.1038/s41541-024-00895-z 10.1101/gr.1239303 10.1038/s41591-021-01377-8 10.1038/s41586-020-03041-6 10.1126/science.abm0829 10.15585/mmwr.mm7315a2 10.1126/science.add2897 10.1038/s41586-020-2700-3 10.1038/s41586-021-03841-4 10.1016/j.cell.2020.08.017 10.1016/j.cell.2022.05.022 10.1038/s41541-023-00731-w 10.1016/j.immuni.2021.08.001 10.1038/ni.3031 10.1038/s41590-021-01084-z 10.1093/cid/ciac397 10.7554/eLife.72619 10.1016/j.vaccine.2009.10.091 10.1038/s41577-020-0348-8 10.1056/NEJMc2108829 10.1016/j.cell.2020.09.038 10.1056/NEJMoa2114228 10.1111/j.1365-2567.2008.02813.x 10.1126/science.abc8511 10.1126/science.abj9853 10.1126/science.abj4176 10.1056/NEJMc2202061 10.1038/s41590-020-0782-6 10.1038/s41591-021-01386-7 10.1038/s41598-023-33320-x 10.1038/s41586-022-04465-y 10.1038/s43587-022-00343-4 10.1038/nri2394 10.1126/science.abm3425 10.1056/NEJMoa2114583 10.1038/s41586-021-04387-1 |
ContentType | Journal Article |
Copyright | 2025 The Authors The Authors Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. Copyright © 2025. Published by Elsevier Ltd. |
Copyright_xml | – notice: 2025 The Authors – notice: The Authors – notice: Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright © 2025. Published by Elsevier Ltd. |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 C1K H94 K9. M7N NAPCQ 7X8 |
DOI | 10.1016/j.vaccine.2025.127420 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Algology Mycology and Protozoology Abstracts (Microbiology C) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Nursing & Allied Health Premium Virology and AIDS Abstracts Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Safety Science Abstracts Immunology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | Nursing & Allied Health Premium MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 127420 |
ExternalDocumentID | 40561567 10_1016_j_vaccine_2025_127420 S0264410X25007170 1_s2_0_S0264410X25007170 |
Genre | Journal Article |
GeographicLocations | United States--US San Francisco California California |
GeographicLocations_xml | – name: San Francisco California – name: United States--US – name: California |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: U54 CA260581 |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 5RE 5VS 7-5 71M 7RV 8C1 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEVXI AEXOQ AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BBNVY BENPR BHPHI BKOJK BLXMC BNPGV CJTIS CNWQP CS3 EBS EFJIC EFKBS EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HCIFZ IHE J1W KOM L7B LUGTX LW9 M29 M2O M41 M7P MO0 N9A O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. Q38 ROL RPZ SAB SCC SDF SDG SDP SES SEW SNL SPCBC SSH SSI SSZ T5K UV1 WH7 Z5R ~G- ~HD .GJ 29Q 53G 7X7 88E 8AO 8FE 8FH 8FI 8FJ 8G5 AAQXK ABUWG ABWVN ABXDB ACRPL ADMUD ADNMO ADVLN AEUYN AFKRA AGHFR AGQPQ AHHHB AQUVI ASPBG AVWKF AZFZN AZQEC BKEYQ BKNYI BPHCQ BVXVI CCPQU DWQXO EJD FEDTE FGOYB FYUFA G-2 GNUQQ GUQSH HEJ HLV HMCUK HMG HMK HMO HVGLF HX~ HZ~ K9- LK8 M0R M0T M1P NAPCQ PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO R2- SAE SIN SVS UKHRP WOW WUQ XPP ZGI ZXP 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 ACMHX ADSLC AGWPP C1K H94 K9. M7N 7X8 |
ID | FETCH-LOGICAL-c499t-6a63e4fdaeedaeb1efb851e9f149cb96526f994177c95068795ee3ff33f665a83 |
IEDL.DBID | .~1 |
ISSN | 0264-410X 1873-2518 |
IngestDate | Fri Sep 05 15:48:26 EDT 2025 Sun Aug 24 03:44:10 EDT 2025 Tue Sep 09 02:32:30 EDT 2025 Wed Aug 27 16:28:06 EDT 2025 Sat Sep 20 17:13:03 EDT 2025 Sat Sep 20 19:12:18 EDT 2025 Sat Sep 20 06:20:47 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 vaccine Sex differences SARS-CoV-2 T-cell |
Language | English |
License | This is an open access article under the CC BY license. Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c499t-6a63e4fdaeedaeb1efb851e9f149cb96526f994177c95068795ee3ff33f665a83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0264410X25007170 |
PMID | 40561567 |
PQID | 3242375100 |
PQPubID | 105530 |
PageCount | 1 |
ParticipantIDs | proquest_miscellaneous_3224254745 proquest_journals_3242375100 pubmed_primary_40561567 crossref_primary_10_1016_j_vaccine_2025_127420 elsevier_sciencedirect_doi_10_1016_j_vaccine_2025_127420 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X25007170 elsevier_clinicalkey_doi_10_1016_j_vaccine_2025_127420 |
PublicationCentury | 2000 |
PublicationDate | 2025-08-13 |
PublicationDateYYYYMMDD | 2025-08-13 |
PublicationDate_xml | – month: 08 year: 2025 text: 2025-08-13 day: 13 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2025 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Hutnick (bb0170) 2010; 28 Bowyer (bb0210) 2018; 6 Tarke (bb0105) 2022; 185 Cohen (bb0040) 2021; 2 Neidleman (bb0155) 2021; 10 Tarke (bb0165) 2021; 2 Levin (bb0140) 2021; 385 Polack (bb0020) 2020; 383 Sekine (bb0060) 2020; 183 Zhang (bb0130) 2022; 185 Guerrera (bb0095) 2021; 6 Liu (bb0125) 2022; 603 Painter (bb0150) 2021; 54 Zambrano (bb0200) 2024; 73 Rakshit (bb0135) 2023; 8 Gilbert (bb0005) 2022; 375 Rydyznski Moderbacher (bb0055) 2020; 183 Chang, Wherry, Goldrath (bb0035) 2014; 15 Goldberg (bb0015) 2021; 385 Gray (bb0080) 2022; 386 Shapiro (bb0205) 2022; 75 Barouch (bb0120) 2021; 385 Pegu (bb0145) 2021; 373 (bb0220) 2020 McMahan (bb0090) 2021; 590 (bb0225) 2022 (bb0230) 2022 Mateus (bb0100) 2021; 374 Shannon (bb0235) 2003; 13 Peng (bb0045) 2022; 23 Prather (bb0025) 2023; 13 Cele (bb0075) 2022; 602 Peng (bb0050) 2020; 21 Bange (bb0070) 2021; 27 Scully, Haverfield, Ursin, Tannenbaum, Klein (bb0175) 2020; 20 Wherry, Barouch (bb0085) 2022; 377 Gardner (bb0190) 2024; 9 Oberhardt (bb0115) 2021; 597 Thieme (bb0065) 2020; 1 Keeton (bb0030) 2022; 603 Mathew (bb0160) 2020; 369 Goel (bb0110) 2021; 374 Takahashi (bb0185) 2020; 588 Khoury (bb0010) 2021; 27 Jo (bb0215) 2023; 3 Fish (bb0180) 2008; 8 Sojka, Huang, Fowell (bb0195) 2008; 124 Gilbert (10.1016/j.vaccine.2025.127420_bb0005) 2022; 375 Mateus (10.1016/j.vaccine.2025.127420_bb0100) 2021; 374 Barouch (10.1016/j.vaccine.2025.127420_bb0120) 2021; 385 Gray (10.1016/j.vaccine.2025.127420_bb0080) 2022; 386 Gardner (10.1016/j.vaccine.2025.127420_bb0190) 2024; 9 Peng (10.1016/j.vaccine.2025.127420_bb0050) 2020; 21 Mathew (10.1016/j.vaccine.2025.127420_bb0160) 2020; 369 Keeton (10.1016/j.vaccine.2025.127420_bb0030) 2022; 603 Goldberg (10.1016/j.vaccine.2025.127420_bb0015) 2021; 385 Thieme (10.1016/j.vaccine.2025.127420_bb0065) 2020; 1 Shannon (10.1016/j.vaccine.2025.127420_bb0235) 2003; 13 McMahan (10.1016/j.vaccine.2025.127420_bb0090) 2021; 590 Painter (10.1016/j.vaccine.2025.127420_bb0150) 2021; 54 Wherry (10.1016/j.vaccine.2025.127420_bb0085) 2022; 377 Goel (10.1016/j.vaccine.2025.127420_bb0110) 2021; 374 Bange (10.1016/j.vaccine.2025.127420_bb0070) 2021; 27 Cohen (10.1016/j.vaccine.2025.127420_bb0040) 2021; 2 Zambrano (10.1016/j.vaccine.2025.127420_bb0200) 2024; 73 Hutnick (10.1016/j.vaccine.2025.127420_bb0170) 2010; 28 Takahashi (10.1016/j.vaccine.2025.127420_bb0185) 2020; 588 Levin (10.1016/j.vaccine.2025.127420_bb0140) 2021; 385 Polack (10.1016/j.vaccine.2025.127420_bb0020) 2020; 383 Tarke (10.1016/j.vaccine.2025.127420_bb0165) 2021; 2 Jo (10.1016/j.vaccine.2025.127420_bb0215) 2023; 3 Rydyznski Moderbacher (10.1016/j.vaccine.2025.127420_bb0055) 2020; 183 Shapiro (10.1016/j.vaccine.2025.127420_bb0205) 2022; 75 Oberhardt (10.1016/j.vaccine.2025.127420_bb0115) 2021; 597 Zhang (10.1016/j.vaccine.2025.127420_bb0130) 2022; 185 (10.1016/j.vaccine.2025.127420_bb0225) 2022 Tarke (10.1016/j.vaccine.2025.127420_bb0105) 2022; 185 Scully (10.1016/j.vaccine.2025.127420_bb0175) 2020; 20 Fish (10.1016/j.vaccine.2025.127420_bb0180) 2008; 8 Bowyer (10.1016/j.vaccine.2025.127420_bb0210) 2018; 6 Guerrera (10.1016/j.vaccine.2025.127420_bb0095) 2021; 6 Rakshit (10.1016/j.vaccine.2025.127420_bb0135) 2023; 8 (10.1016/j.vaccine.2025.127420_bb0230) 2022 Khoury (10.1016/j.vaccine.2025.127420_bb0010) 2021; 27 Pegu (10.1016/j.vaccine.2025.127420_bb0145) 2021; 373 Neidleman (10.1016/j.vaccine.2025.127420_bb0155) 2021; 10 Sojka (10.1016/j.vaccine.2025.127420_bb0195) 2008; 124 Liu (10.1016/j.vaccine.2025.127420_bb0125) 2022; 603 Chang (10.1016/j.vaccine.2025.127420_bb0035) 2014; 15 Prather (10.1016/j.vaccine.2025.127420_bb0025) 2023; 13 Sekine (10.1016/j.vaccine.2025.127420_bb0060) 2020; 183 Peng (10.1016/j.vaccine.2025.127420_bb0045) 2022; 23 Cele (10.1016/j.vaccine.2025.127420_bb0075) 2022; 602 |
References_xml | – volume: 602 start-page: 654 year: 2022 end-page: 656 ident: bb0075 article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization publication-title: Nature – volume: 6 start-page: eabl5344 year: 2021 ident: bb0095 article-title: BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype publication-title: Sci Immunol – year: 2022 ident: bb0225 publication-title: Moderna – year: 2022 ident: bb0230 publication-title: Pfizer-BioNTech – volume: 9 start-page: 99 year: 2024 ident: bb0190 article-title: Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines publication-title: NPJ Vaccines – volume: 73 start-page: 330 year: 2024 end-page: 338 ident: bb0200 article-title: Durability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021-2023 publication-title: MMWR Morb Mortal Wkly Rep – volume: 21 start-page: 1336 year: 2020 end-page: 1345 ident: bb0050 article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 publication-title: Nat Immunol – volume: 385 year: 2021 ident: bb0140 article-title: Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months publication-title: N Engl J Med – volume: 27 start-page: 1280 year: 2021 end-page: 1289 ident: bb0070 article-title: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer publication-title: Nat Med – volume: 375 start-page: 43 year: 2022 end-page: 50 ident: bb0005 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science – volume: 23 start-page: 50 year: 2022 end-page: 61 ident: bb0045 article-title: An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease publication-title: Nat Immunol – volume: 1 year: 2020 ident: bb0065 article-title: Robust T cell response toward spike, membrane, and Nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients publication-title: Cell Rep Med – volume: 54 start-page: 2133 year: 2021 end-page: 2142 ident: bb0150 article-title: Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination publication-title: Immunity – volume: 28 start-page: 1932 year: 2010 end-page: 1941 ident: bb0170 article-title: Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive publication-title: Vaccine – volume: 185 start-page: 2434 year: 2022 end-page: 2451 ident: bb0130 article-title: Humoral and cellular immune memory to four COVID-19 vaccines publication-title: Cell – volume: 8 start-page: 737 year: 2008 end-page: 744 ident: bb0180 article-title: The X-files in immunity: sex-based differences predispose immune responses publication-title: Nat Rev Immunol – volume: 10 year: 2021 ident: bb0155 article-title: mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status publication-title: Elife – volume: 377 start-page: 821 year: 2022 end-page: 822 ident: bb0085 article-title: T cell immunity to COVID-19 vaccines publication-title: Science – volume: 75 start-page: S61 year: 2022 end-page: S71 ident: bb0205 article-title: Association of Frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced immunity in older adults publication-title: Clin Infect Dis – volume: 15 start-page: 1104 year: 2014 end-page: 1115 ident: bb0035 article-title: Molecular regulation of effector and memory T cell differentiation publication-title: Nat Immunol – volume: 373 start-page: 1372 year: 2021 end-page: 1377 ident: bb0145 article-title: Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants publication-title: Science – volume: 374 start-page: eabj9853 year: 2021 ident: bb0100 article-title: Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells publication-title: Science – volume: 8 start-page: 134 year: 2023 ident: bb0135 article-title: Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN((R)) induced immunity in COVID-19 exposed Indians publication-title: NPJ Vaccines – volume: 385 start-page: 951 year: 2021 end-page: 953 ident: bb0120 article-title: Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination publication-title: N Engl J Med – volume: 603 start-page: 493 year: 2022 end-page: 496 ident: bb0125 article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron publication-title: Nature – volume: 13 start-page: 6505 year: 2023 ident: bb0025 article-title: Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study publication-title: Sci Rep – volume: 603 start-page: 488 year: 2022 end-page: 492 ident: bb0030 article-title: T cell responses to SARS-CoV-2 spike cross-recognize omicron publication-title: Nature – volume: 386 start-page: 2243 year: 2022 end-page: 2245 ident: bb0080 article-title: Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa publication-title: N Engl J Med – volume: 597 start-page: 268 year: 2021 end-page: 273 ident: bb0115 article-title: Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine publication-title: Nature – volume: 13 start-page: 2498 year: 2003 end-page: 2504 ident: bb0235 article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks publication-title: Genome Res – volume: 2 year: 2021 ident: bb0040 article-title: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells publication-title: Cell Rep Med – volume: 2 year: 2021 ident: bb0165 article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals publication-title: Cell Rep Med – volume: 369 year: 2020 ident: bb0160 article-title: Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications publication-title: Science – volume: 185 start-page: 847 year: 2022 end-page: 859 ident: bb0105 article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron publication-title: Cell – volume: 183 start-page: 996 year: 2020 end-page: 1012 e1019 ident: bb0055 article-title: Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity publication-title: Cell – year: 2020 ident: bb0220 article-title: J. F. Inside the new mRNA vaccines for COVID-19 – volume: 183 start-page: 158 year: 2020 end-page: 168 e114 ident: bb0060 article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 publication-title: Cell – volume: 6 year: 2018 ident: bb0210 article-title: Activation-induced markers detect vaccine-specific CD4(+) T cell responses not measured by assays conventionally used in clinical trials publication-title: Vaccines (Basel) – volume: 588 start-page: 315 year: 2020 end-page: 320 ident: bb0185 article-title: Sex differences in immune responses that underlie COVID-19 disease outcomes publication-title: Nature – volume: 374 start-page: abm0829 year: 2021 ident: bb0110 article-title: mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern publication-title: Science – volume: 124 start-page: 13 year: 2008 end-page: 22 ident: bb0195 article-title: Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target publication-title: Immunology – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: bb0020 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N Engl J Med – volume: 20 start-page: 442 year: 2020 end-page: 447 ident: bb0175 article-title: Considering how biological sex impacts immune responses and COVID-19 outcomes publication-title: Nat Rev Immunol – volume: 590 start-page: 630 year: 2021 end-page: 634 ident: bb0090 article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques publication-title: Nature – volume: 385 year: 2021 ident: bb0015 article-title: Waning immunity after the BNT162b2 vaccine in Israel publication-title: N Engl J Med – volume: 27 start-page: 1205 year: 2021 end-page: 1211 ident: bb0010 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat Med – volume: 3 start-page: 82 year: 2023 end-page: 92 ident: bb0215 article-title: Impaired CD4(+) T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination publication-title: Nat Aging – volume: 6 start-page: eabl5344 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0095 article-title: BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype publication-title: Sci Immunol doi: 10.1126/sciimmunol.abl5344 – volume: 603 start-page: 488 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0030 article-title: T cell responses to SARS-CoV-2 spike cross-recognize omicron publication-title: Nature doi: 10.1038/s41586-022-04460-3 – volume: 2 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0165 article-title: Impact of SARS-CoV-2 variants on the total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals publication-title: Cell Rep Med – volume: 383 start-page: 2603 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0020 article-title: Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – volume: 185 start-page: 847 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0105 article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from alpha to omicron publication-title: Cell doi: 10.1016/j.cell.2022.01.015 – volume: 9 start-page: 99 year: 2024 ident: 10.1016/j.vaccine.2025.127420_bb0190 article-title: Identification of cross reactive T cell responses in adenovirus based COVID 19 vaccines publication-title: NPJ Vaccines doi: 10.1038/s41541-024-00895-z – volume: 13 start-page: 2498 year: 2003 ident: 10.1016/j.vaccine.2025.127420_bb0235 article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks publication-title: Genome Res doi: 10.1101/gr.1239303 – volume: 27 start-page: 1205 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0010 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat Med doi: 10.1038/s41591-021-01377-8 – volume: 590 start-page: 630 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0090 article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques publication-title: Nature doi: 10.1038/s41586-020-03041-6 – volume: 374 start-page: abm0829 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0110 article-title: mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern publication-title: Science doi: 10.1126/science.abm0829 – volume: 73 start-page: 330 year: 2024 ident: 10.1016/j.vaccine.2025.127420_bb0200 article-title: Durability of original monovalent mRNA vaccine effectiveness against COVID-19 omicron-associated hospitalization in children and adolescents - United States, 2021-2023 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7315a2 – year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0230 – volume: 377 start-page: 821 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0085 article-title: T cell immunity to COVID-19 vaccines publication-title: Science doi: 10.1126/science.add2897 – volume: 588 start-page: 315 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0185 article-title: Sex differences in immune responses that underlie COVID-19 disease outcomes publication-title: Nature doi: 10.1038/s41586-020-2700-3 – volume: 597 start-page: 268 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0115 article-title: Rapid and stable mobilization of CD8(+) T cells by SARS-CoV-2 mRNA vaccine publication-title: Nature doi: 10.1038/s41586-021-03841-4 – volume: 183 start-page: 158 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0060 article-title: Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 publication-title: Cell doi: 10.1016/j.cell.2020.08.017 – volume: 185 start-page: 2434 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0130 article-title: Humoral and cellular immune memory to four COVID-19 vaccines publication-title: Cell doi: 10.1016/j.cell.2022.05.022 – volume: 8 start-page: 134 year: 2023 ident: 10.1016/j.vaccine.2025.127420_bb0135 article-title: Polyfunctional CD4 T-cells correlating with neutralising antibody is a hallmark of COVISHIELD(TM) and COVAXIN((R)) induced immunity in COVID-19 exposed Indians publication-title: NPJ Vaccines doi: 10.1038/s41541-023-00731-w – volume: 54 start-page: 2133 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0150 article-title: Rapid induction of antigen-specific CD4(+) T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination publication-title: Immunity doi: 10.1016/j.immuni.2021.08.001 – volume: 15 start-page: 1104 year: 2014 ident: 10.1016/j.vaccine.2025.127420_bb0035 article-title: Molecular regulation of effector and memory T cell differentiation publication-title: Nat Immunol doi: 10.1038/ni.3031 – volume: 23 start-page: 50 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0045 article-title: An immunodominant NP(105-113)-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease publication-title: Nat Immunol doi: 10.1038/s41590-021-01084-z – volume: 75 start-page: S61 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0205 article-title: Association of Frailty, age, and biological sex with severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine-induced immunity in older adults publication-title: Clin Infect Dis doi: 10.1093/cid/ciac397 – volume: 10 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0155 article-title: mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status publication-title: Elife doi: 10.7554/eLife.72619 – volume: 28 start-page: 1932 year: 2010 ident: 10.1016/j.vaccine.2025.127420_bb0170 article-title: Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive publication-title: Vaccine doi: 10.1016/j.vaccine.2009.10.091 – volume: 20 start-page: 442 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0175 article-title: Considering how biological sex impacts immune responses and COVID-19 outcomes publication-title: Nat Rev Immunol doi: 10.1038/s41577-020-0348-8 – volume: 385 start-page: 951 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0120 article-title: Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination publication-title: N Engl J Med doi: 10.1056/NEJMc2108829 – volume: 183 start-page: 996 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0055 article-title: Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity publication-title: Cell doi: 10.1016/j.cell.2020.09.038 – volume: 385 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0015 article-title: Waning immunity after the BNT162b2 vaccine in Israel publication-title: N Engl J Med doi: 10.1056/NEJMoa2114228 – volume: 124 start-page: 13 year: 2008 ident: 10.1016/j.vaccine.2025.127420_bb0195 article-title: Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target publication-title: Immunology doi: 10.1111/j.1365-2567.2008.02813.x – volume: 1 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0065 article-title: Robust T cell response toward spike, membrane, and Nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients publication-title: Cell Rep Med – volume: 369 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0160 article-title: Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications publication-title: Science doi: 10.1126/science.abc8511 – volume: 6 year: 2018 ident: 10.1016/j.vaccine.2025.127420_bb0210 article-title: Activation-induced markers detect vaccine-specific CD4(+) T cell responses not measured by assays conventionally used in clinical trials publication-title: Vaccines (Basel) – volume: 374 start-page: eabj9853 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0100 article-title: Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells publication-title: Science doi: 10.1126/science.abj9853 – volume: 373 start-page: 1372 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0145 article-title: Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants publication-title: Science doi: 10.1126/science.abj4176 – volume: 386 start-page: 2243 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0080 article-title: Effectiveness of Ad26.COV2.S and BNT162b2 vaccines against omicron variant in South Africa publication-title: N Engl J Med doi: 10.1056/NEJMc2202061 – volume: 21 start-page: 1336 year: 2020 ident: 10.1016/j.vaccine.2025.127420_bb0050 article-title: Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 publication-title: Nat Immunol doi: 10.1038/s41590-020-0782-6 – year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0225 – volume: 27 start-page: 1280 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0070 article-title: CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer publication-title: Nat Med doi: 10.1038/s41591-021-01386-7 – volume: 13 start-page: 6505 year: 2023 ident: 10.1016/j.vaccine.2025.127420_bb0025 article-title: Predictors of long-term neutralizing antibody titers following COVID-19 vaccination by three vaccine types: the BOOST study publication-title: Sci Rep doi: 10.1038/s41598-023-33320-x – volume: 603 start-page: 493 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0125 article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 omicron publication-title: Nature doi: 10.1038/s41586-022-04465-y – volume: 3 start-page: 82 year: 2023 ident: 10.1016/j.vaccine.2025.127420_bb0215 article-title: Impaired CD4(+) T cell response in older adults is associated with reduced immunogenicity and reactogenicity of mRNA COVID-19 vaccination publication-title: Nat Aging doi: 10.1038/s43587-022-00343-4 – volume: 8 start-page: 737 year: 2008 ident: 10.1016/j.vaccine.2025.127420_bb0180 article-title: The X-files in immunity: sex-based differences predispose immune responses publication-title: Nat Rev Immunol doi: 10.1038/nri2394 – volume: 375 start-page: 43 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0005 article-title: Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial publication-title: Science doi: 10.1126/science.abm3425 – volume: 385 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0140 article-title: Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months publication-title: N Engl J Med doi: 10.1056/NEJMoa2114583 – volume: 2 year: 2021 ident: 10.1016/j.vaccine.2025.127420_bb0040 article-title: Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells publication-title: Cell Rep Med – volume: 602 start-page: 654 year: 2022 ident: 10.1016/j.vaccine.2025.127420_bb0075 article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization publication-title: Nature doi: 10.1038/s41586-021-04387-1 |
SSID | ssj0005319 |
Score | 2.47828 |
Snippet | Severe SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies investigate... AbstractSevere SARS-CoV-2 infection has been partially controlled by vaccination, though issues in duration and breadth of protection remain. Few studies... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 127420 |
SubjectTerms | Adult Allergy and Immunology Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology CD4 antigen CD4-Positive T-Lymphocytes - immunology CD8 antigen CD8-Positive T-Lymphocytes - immunology Cells COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccine COVID-19 vaccines COVID-19 Vaccines - immunology Cytokines Cytokines - immunology Cytokines - metabolism FDA approval Female Humans Immune response Immune response (cell-mediated) Immune system Immunity (Disease) Immunity, Cellular Immunological memory Immunoregulation Infections Lymphocytes T Male Middle Aged mRNA mRNA vaccines Proteins Questionnaires SARS-CoV-2 SARS-CoV-2 - immunology Severe acute respiratory syndrome coronavirus 2 Sex differences Sex Factors Sociodemographics Spike Glycoprotein, Coronavirus - immunology Stains & staining T-cell Vaccination Vaccines Vectors (Biology) Viral diseases Viral infections Young Adult |
Title | COVID-19 mRNA or viral vector vaccine type and subject sex influence the SARS-CoV-2 T-cell response |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X25007170 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X25007170 https://dx.doi.org/10.1016/j.vaccine.2025.127420 https://www.ncbi.nlm.nih.gov/pubmed/40561567 https://www.proquest.com/docview/3242375100 https://www.proquest.com/docview/3224254745 |
Volume | 61 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9NQyBeEJSvjjEZCe1pbpPYcZrHqjB1oJVp7aq-WXbiSJ0gnZp22l74W_hb-Mu4y0cLggnEYxKfEufOd_ez7wPgrU8lyxNheYqIlsssjrmxWcpDkTj0HpwSZSml05EaXsgPs3C2A4MmF4bCKmvdX-n0UlvXd7r13-xezefdsVfacm-GRpxACeF2KSOS9c7Xn8I8RNncgwZzGr3N4uledq5NQsfXCBODsOPTqaV3l326y_8s7dDxY3hUO5CsX33jE9hxeQvuVy0lb1vw4LQ-LG_B4VlVlvr2iE22WVbFETtkZ9uC1UjTmlJMTJmYyxryp5AOPk1P3nE_Zl_OR322WDKKB_7Mrst9flZPitEeLjN5yoq1pT0dVrgbNm9anzD0L9m4fz7mg8WUB9-_TTgdFbBlFZrrnsHF8fvJYMjrngw8QWy04soo4WSWGrStBvW8yyz6bC7OEGklNlZhoJDf0o-iJA49Ra3MnRNZJkSmVGh64jns5ovcvQQWCfSFMt_61rPSBAjdYpeY2PVStKbOyTZ0Gk7oq6r0hm5i0i51PUtNrNMV69qgGn7pJq8UNaFG4_A3wuhPhK6o13OhfV0E2tO_yVwbehvKX8T2X16634iU3ryndG8j1JP4-M3mMa544o3J3WJNYwgmykiGbXhRieLm_0gChKGK9v7_u17BQ7qifXNf7MPuarl2r9HxWtmDcmUdwL3-ycfh6AdskSrH |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9NQ3y8oFFgFDYwEtrT3Cax4zSPVcfUwVqmtav6ZjmJI3WCdGraib3wt_C38JftLh8tCCYQr7FPSXznu_vZ9wHwzqWS5bGIeIKIlss0DLmJ0oT7IrboPVglilJKg6HqX8gPU3-6Bb06F4bCKivdX-r0QltXT9rVaravZrP2yClsuTNFI06gBHH7PUltDlCoW99-ivMQRXcPms1p-iaNp33ZujYx3V8jTvT8lkvXls5dBuouB7QwRMc78LjyIFm3_MgnsGWzBtwve0reNODBoLotb8DBWVmX-uaQjTdpVvkhO2Bnm4rVSNOYUFBMkZnLavKnkPQ-TU6OuBuyL-fDLpsvGAUEf2bXxUE_q36K0SEuM1nC8lVEhzost1_ZrO59wtDBZKPu-Yj35hPu_fg-5nRXwBZlbK59BhfH78e9Pq-aMvAYwdGSK6OElWli0LgaVPQ2jdBps2GKUCuOQuV7Chku3SCIQ99R1MvcWpGmQqRK-aYjnsN2Ns_sC2CBQGcodSM3ciJpPMRuoY1NaDsJmlNrZRNaNSf0VVl7Q9dBaZe6-ktNrNMl65qgan7pOrEUVaFG6_A3wuBPhDavNnSuXZ172tG_CV0TOmvKX-T2X166V4uUXr-n8G8DVJQ4_HY9jFueeGMyO1_RHMKJMpB-E3ZLUVyvjyRE6Kvg5f9_1xt42B8PTvXpyfDjK3hEI3SI7oo92F4uVnYfvbBl9LrYZbfq8yxQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+mRNA+or+viral+vector+vaccine+type+and+subject+sex+influence+the+SARS-CoV-2%C2%A0T-cell+response&rft.jtitle=Vaccine&rft.au=Tong%2C+Sherry&rft.au=Litwin%2C+Sean+M&rft.au=Epel%2C+Elissa+S&rft.au=Lin%2C+Jue&rft.date=2025-08-13&rft.issn=0264-410X&rft.volume=61&rft.spage=127420&rft.epage=127420&rft_id=info:doi/10.1016%2Fj.vaccine.2025.127420&rft.externalDBID=ECK1-s2.0-S0264410X25007170&rft.externalDocID=1_s2_0_S0264410X25007170 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X25X00165%2Fcov150h.gif |